Genetic Testing
Most people with an inherited cancer gene mutation don’t know they have one.
Testing takes one appointment.
Knowing changes everything.
Your Testing Options
Inherited Cancer Risk Panel
Screen for inherited mutations across 35 cancer-related genes, including BRCA1, BRCA2, PALB2, and Lynch syndrome.
Available as an at-home or in-clinic saliva test, with results reviewed by your Coyne Medical GP.
From £650
Advanced Genetic Screening
Screen 54 cancer-related genes for inherited risk, plus a 21-gene pharmacogenomics panel showing how your genes affect your response to medication.
In-clinic blood test only.
£1,300
Why Genetic Testing Matters
Family History of Cancer
If a close relative was diagnosed with cancer, particularly at a young age, you may carry an inherited gene mutation without knowing it.
Your full genetic risk
Around 95% of people with an inherited cancer gene mutation in the UK have never been tested. Knowing your risk changes what you can do about it.
GP-supported throughout
Every result is reviewed with your Coyne Medical GP. You will never receive a report and be left to interpret it alone. Based in London, serving patients across the UK.
Accredited laboratories
All testing is carried out by specialist laboratories accredited to UKAS, ISO 15189 and CAP standards; the highest available in clinical genetics.
Why We Built This
Our co-founder, Dr Lucy Hooper, discovered her own PALB2 gene mutation while researching genetic screening for her patients. With a lifetime breast cancer risk of over 60%, she chose risk-reducing surgery, bringing her risk to under 5%.
Her experience is not unusual. What is unusual is that she knew to look. Most people in the same position never get the chance to make that choice, because they are never offered the test.
That is why genetic cancer screening is central to everything we do at Coyne Medical. Not as an add-on or an afterthought, but as one of the most important things we can offer the people who come to us.
Your Questions About Genetic Testing
Genes are sections of DNA that carry the instructions for how our bodies grow and function. Genetic testing looks at variations in these genes that may indicate a predisposition to certain diseases, including inherited cancers. It can also tell us how your body is likely to respond to certain medications.
The NHS offers genetic testing to people who meet specific criteria, usually those with a strong and documented family history of cancer. Many people with genuine concerns do not meet these thresholds or face long waiting times. Our testing is available to anyone who wants it, with no referral needed and no criteria to meet. Results are typically returned within four weeks.
In most cases, no. The Association of British Insurers and the British Medical Association have agreed that insurers are not allowed to ask for or use the results of predictive genetic tests when you apply for insurance. The only exception is life insurance over £500,000 where you have previously had a predictive genetic test for Huntington’s Disease. Insurers may still ask about your family history, but your genetic test results remain private. If you test negative for a gene your family history suggested you might carry, you may choose to disclose this, as it could work in your favour. You can read more about the ABI code on genetic testing and insurance on the ABI website.
We take the security of your genetic information extremely seriously. We will never sell or share your medical information or data. Your results are shared securely through our patient portal. The specialist laboratories we work with operate under strict rules governing the privacy of sensitive genetic data. You will be asked to consent to their receiving your sample and data before testing begins. You may choose to opt out of any anonymised research use of your data.
Consumer DNA tests use a method called genotyping, which looks at common genetic variants and is designed for ancestry and general interest purposes. Our testing uses full-gene sequencing and deletion and duplication analysis via next-generation sequencing technology (NGS). This is the most accurate method available for identifying clinically significant inherited cancer gene variants. Consumer tests are not designed to guide medical decisions and should not be used for that purpose.
For the inherited cancer risk panel, there are two main outcomes. A negative result means the test did not identify any gene variants that increase your cancer risk for the genes tested. It does not mean you will never develop cancer, as many factors beyond genetics affect risk. A positive result means a gene variant has been identified that is associated with an increased risk of certain cancers. Your GP will explain what this means for you personally and what your options are, which may include increased surveillance, preventive measures, or referral to a specialist. We do not report variants of uncertain significance, as these are not currently actionable from a clinical standpoint.
For the pharmacogenomics panel, results are different in nature. Rather than a positive or negative outcome, you receive a personalised report showing how your genetic makeup is likely to affect your response to a range of medications, including dosing, effectiveness, and side effect risk. Your GP will go through this report with you and advise on any implications for your current or future prescriptions.
A positive result has implications for your first-degree relatives — your parents, siblings, and children — who each have a 50% chance of carrying the same variant. Your GP will discuss this with you and can provide a letter explaining the findings that you can share with family members who may want to consider testing themselves.
Results are typically returned within four weeks of your sample reaching the laboratory. For at-home testing, please allow additional time for delivery of your kit and return postage. We will contact you as soon as your results are ready to arrange your results consultation.
54 Cancer Gene Panel
Tumour genes include those related to:
Breast cancer
Ovarian cancer
Uterine cancer
Colorectal cancer
Cutaneous melanoma
Gastric cancer
Pancreatic cancer
Prostate cancer
Renal cell cancer
Thyroid cancer
Full List of Genes Tested
| APC | CDH1 | MLH1 | POLD1 | SDHB | TSC2 |
| ATM | CDKN2A | MSH2 | POLE | SDHC | VHL |
| AXIN2 | CHEK2 | MSH6 | PTCH1 | SDHD | WT1 |
| BAP1 | DICER1 | MUTYH | PTEN | SMAD4 | |
| BARD1 | EPCAM | NBN | RAD51C | SMARCA4 | |
| BMPR1A | FH | NF1 | RAD51D | SMARCB1 | |
| BRCA1 | FLCN | NF2 | RB1 | STK11 | |
| BRCA2 | KIT | PALB2 | RET | TMEM127 | |
| BRIP1 | MEN1 | PDGFRA | SDHA | TP53 | |
| CDC73 | MET | PMS2 | SDHAF2 | TSC1 |
35 Cancer Gene Panel
Tumour genes include those related to:
Breast cancer
Ovarian cancer
Uterine cancer
Colorectal cancer
Cutaneous melanoma
Gastric cancer
Pancreatic cancer
Prostate cancer
Renal cell cancer
Thyroid cancer
Full List of Genes Tested
APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GREM1, HOXB13, MITF (E318K variant), MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51C, RAD51D, RNF43, SMAD4, STK11, TP53, VHL
Tumour genes include those related to:
Breast cancer
Ovarian cancer
Uterine cancer
Colorectal cancer
Cutaneous melanoma
Gastric cancer
Pancreatic cancer
Prostate cancer
Renal cell cancer
Thyroid cancer
Full List of Genes Tested
| APC | CDH1 | MLH1 | POLD1 | SDHB | TSC2 |
| ATM | CDKN2A | MSH2 | POLE | SDHC | VHL |
| AXIN2 | CHEK2 | MSH6 | PTCH1 | SDHD | WT1 |
| BAP1 | DICER1 | MUTYH | PTEN | SMAD4 | |
| BARD1 | EPCAM | NBN | RAD51C | SMARCA4 | |
| BMPR1A | FH | NF1 | RAD51D | SMARCB1 | |
| BRCA1 | FLCN | NF2 | RB1 | STK11 | |
| BRCA2 | KIT | PALB2 | RET | TMEM127 | |
| BRIP1 | MEN1 | PDGFRA | SDHA | TP53 | |
| CDC73 | MET | PMS2 | SDHAF2 | TSC1 |
21 Pharmacogenetics Panel
Pharmacogenetics illustrates how genetic changes can affect the influence of drugs. Genetic changes in the proteins responsible for absorption, distribution, metabolism, and excretion of drugs can have a huge impact on their effectiveness and compatibility. Some drugs have different effects on different people, e.g. antidepressants, analgesics, neuroleptics, chemotherapeutics, AIDS medication, thrombosis medication, anaesthetics, beta-blockers, and statins. Reduced or missing activity of a specific enzyme may increase the drug dosage and cause unwanted side effects. On the other hand, a medication that is activated by metabolism may not work if an enzyme is inactive. Enhanced enzyme activity can also affect the response to medication, e.g. by degrading the active ingredients.
Full List of Genes
| ABCG2 | CYP2D6 | G6PD | NUDT15 | VKORC1 |
| CACNA1S | CYP3A4 | HLA-A | RYR1 | |
| CYP2B6 | CYP3A5 | HLA-B | SLCO1B1 | |
| CYP2C19 | CYP4F2 | IFNL3 | TPMT | |
| CYP2C9 | DPYD | MT-RNR1 | UGT1A1 |
Complete Your Health Picture
Genetic testing is one part of a complete picture of your health. The Ultimate Screening package includes the 55 gene cancer panel and pharmacogenomics as standard, and genetic testing is available as an add-on to our Advanced and Complete packages.